Odyssey Therapeutics

Odyssey Therapeutics (Nasdaq: ODTX) is a Boston-based clinical-stage biopharmaceutical company founded in 2021 that focuses on developing oral small molecule treatments for autoimmune and inflammatory diseases, including its lead program OD-001 targeting RIPK2 for inflammatory bowel disease and ulcerative colitis. The company raised $304 million in its 2026 Nasdaq IPO, having previously secured approximately $726.5 million in private funding across more than 30 investors.